Research summary
Large randomized trials and pooled cohort analyses on diabetes, hypertension, and cardiovascular outcomes dominate the record. The ADVANCE trial randomized 11,140 patients with type 2 diabetes to standard or intensive glucose control targeting HbA1c <=6.5% using gliclazide-based regimens, and assessed major macrovascular and microvascular endpoints jointly and separately [1]; secondary analysis of the same cohort related severe hypoglycemia to subsequent vascular events and death using Cox models, showing strong associations between hypoglycemic episodes and adverse outcomes [6]. The INTERACT2 trial in 2,839 patients with spontaneous intracerebral hemorrhage within six hours compared rapid blood-pressure lowering (systolic <140 mm Hg) to guideline care, using death or major disability on the modified Rankin scale as the primary endpoint [4]. A pooled analysis of 1,201 population-representative studies covering 104 million participants tracked global hypertension prevalence, treatment, and control from 1990 to 2019 across 200 countries using a Bayesian hierarchical model [2]. An individual-participant meta-analysis of 239 prospective studies (10.6 million participants; 3.95 million never-smokers without baseline disease) quantified the BMI-mortality relationship across four continents, controlling for confounding and reverse causality [3]. A meta-analysis of 37 prospective cohort studies estimated sex-specific relative risks for fatal coronary heart disease in people with diabetes, finding a larger excess risk in women [5]. The work uses pragmatic trial design and large pooled cohorts to define modern targets for blood-pressure and glucose control.
Recent publications
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesDOI
- Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysisDOI
- Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participantsDOI
- Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continentsDOI
- Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral HemorrhageDOI
- Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studiesDOI
- Severe Hypoglycemia and Risks of Vascular Events and DeathDOI
- Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysisDOI
- Intensive glucose control and macrovascular outcomes in type 2 diabetesDOI
- Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysisDOI
The lab page does not clearly state student acceptance status. Email the professor directly to confirm.
How to apply
Email Mark Woodward 6-12 months before your application deadline. Read several recent papers and reference specific work in your message. Use our how to email a Japanese professor guide for the proven email structure.
For applications via MEXT scholarship: see our MEXT 2027 complete guide and university-specific University Recommendation track.
External profiles
- ORCID: https://orcid.org/0000-0001-9800-5296
- OpenAlex: openalex.org
Profile compiled from public sources (Researchmap, OpenAlex, Tohoku University faculty directory). Last refreshed 2026-05. Report incorrect information.